|
WO2020210608A1
|
|
Liquid concentrates of calcium and magnesium
|
|
US2013296433A1
|
|
Phosphorus binder composition for treatment of hyperphosphatemia
|
|
US2013296390A1
|
|
Method and compositions for enhancing the safety of orally administered magnesium alpha-lipoate
|
|
US2011269837A1
|
|
Phosphorus binder composition for treatment of hyperphosphatemia
|
|
EP2456471A2
|
|
Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
|
|
EP2456433A2
|
|
Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine
|
|
WO2010008976A2
|
|
Combined calcium, magnesium and vitamin d supplements
|
|
WO2009062203A1
|
|
Iron-containing nutritional supplement
|
|
EP2349322A1
|
|
Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
|
|
WO2008116215A2
|
|
Phosphorus binder for treatment of renal disease
|
|
US2009239914A1
|
|
Phosphorus binder for treatment of renal disease
|
|
US2008234371A1
|
|
Non-hygroscopic L-carnitine salts
|
|
US2008234378A1
|
|
Methods for the preparation and formulation of l-carnitine valproate salts
|
|
US2008234382A1
|
|
Methods for the preparation, formulation and use of lithium valproate
|
|
US2006228424A1
|
|
Phosphorus binder for treatment of kidney disease
|
|
US2007083063A1
|
|
Methods for the preparation and formulation of magnesium valproate hydrate
|
